Posttransplant lymphoproliferative disorders occurring under primary FK 506 immunosuppression.

Abstract

POSlTRANSPLANT Iymphoproliferative disease (PTLD) is a well-recognized complication of immunosuppression. I Previous reports of patients immunosuppressed with cyclosporine (eyA) revealed a 1.7% incidence of PTLD in solid-organ transplant recipients and a strong association with the Epstein-Barr virus «EBV). ~ The use of FK 506 in clinical trials has resulted in improved patient and graft survival. as well as a reduction in the prevalence of infectious complications and as a result infection-related mortality . .I·~ PTLD has also been seen among the complications observed in patients treated with FK 506. having a reported incidence of 0.7% to 1.5%. ~.fI This report descnbes the clinical and pathologic features of PTLD arising In the solid-organ transplant recipients treated primarily with FK 506.

Cite this paper

@article{Reyes1991PosttransplantLD, title={Posttransplant lymphoproliferative disorders occurring under primary FK 506 immunosuppression.}, author={Jorge D. Reyes and Andreas G. Tzakis and Mark R . Green and Bakr Nour and Michael Andrew Nalesnik and David H. van Thiel and Manuel Cuesta Mart{\'i}n and Mary Kay Breinig and John J . Fung and Margaret H. Cooper}, journal={Transplantation proceedings}, year={1991}, volume={23 6}, pages={3044-6} }